Literature DB >> 25833139

Impact of metabolic syndrome on the hospitalization rate of Crohn's disease patients seen at a tertiary care center: a retrospective cohort study.

Paul Stephen Fitzmorris1, Lisandro Damian Colantonio, Euriko Torrazza Perez, Ioana Smith, Donny Debajyoti Kakati, Talha Aziz Malik.   

Abstract

BACKGROUND/AIMS: Recent studies suggest that markers of mesenteric inflammation, such as increased adipose tissue, may be associated with poor outcomes in Crohn's disease (CD). This study's hypothesis is that CD patients with metabolic syndrome (MetS) have more CD-related hospitalizations than CD patients without MetS.
METHODS: We conducted a retrospective cohort study of CD patients seen from 2000 to 2012 at our tertiary care center. We analyzed crude and age-, sex- and duration of CD-adjusted incidence rate ratio (IRR) of CD-related hospitalization of those with MetS versus those without MetS. We also investigated possible associations between individual component conditions of MetS and rate of CD-related hospitalization.
RESULTS: A total of 868 CD patients were included. There were 37 (4%) patients with MetS at initial observation. After multi-variable adjustment, patients with MetS had a CD-related hospitalization rate twice that of those who did not have MetS. High triglycerides (TG), low high density lipoprotein (HDL) cholesterol and diabetes mellitus (DM) were associated with increased risk of CD-related hospitalization.
CONCLUSIONS: CD patients with MetS have a higher rate of CD-related hospitalization compared to those without MetS. Hypertriglyceridemia, low HDL cholesterol and DM may be good markers of local and systemic inflammation as seen in CD.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25833139     DOI: 10.1159/000380763

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

Review 1.  Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Authors:  Siddharth Singh; Parambir S Dulai; Amir Zarrinpar; Sonia Ramamoorthy; William J Sandborn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

Review 2.  Obesity, a challenge in the management of inflammatory bowel diseases.

Authors:  Mohsen Rajabnia; Shideh Moftakhari Hajimirzaei; Mohammad Reza Hatamnejad; Shabnam Shahrokh; Shaghayegh Baradaran Ghavami; Maryam Farmani; Naghmeh Salarieh; Nastaran Ebrahimi; Nesa Kazemifard; Azam Farahanie; Ghazal Sherkat; Hamid Asadzadeh Aghdaei
Journal:  Immunol Res       Date:  2022-08-29       Impact factor: 4.505

3.  Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications.

Authors:  Anand Kumar; Tatiana Teslova; Erin Taub; Joshua D Miller; Dana J Lukin
Journal:  Dig Dis Sci       Date:  2020-07-02       Impact factor: 3.199

Review 4.  The Role of Supplemental Complex Dietary Carbohydrates and Gut Microbiota in Promoting Cardiometabolic and Immunological Health in Obesity: Lessons from Healthy Non-Obese Individuals.

Authors:  Petra C Vinke; Sahar El Aidy; Gertjan van Dijk
Journal:  Front Nutr       Date:  2017-07-24

Review 5.  Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms.

Authors:  Andrew Szilagyi
Journal:  Clin J Gastroenterol       Date:  2019-08-26

Review 6.  Interaction of obesity and inflammatory bowel disease.

Authors:  Jason W Harper; Timothy L Zisman
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.